Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
10.39
-0.10 (-1.00%)
Mar 20, 2026, 1:56 PM EDT - Market open
Valneva SE Market Cap
Valneva SE has a market cap or net worth of $900.89 million as of March 20, 2026. Its market cap has increased by 56.08% in one year.
Market Cap
900.89M
Enterprise Value
1.02B
1-Year Change
56.08%
Ranking
Category
Stock Price
$10.39
Market Cap Chart
Since the IPO on June 3, 2014, Valneva SE's market cap has increased from $450.94M to $900.89M, an increase of 99.78%. That is a compound annual growth rate of 6.04%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 19, 2026 | 902.13M | 19.62% |
| Dec 31, 2025 | 754.16M | 107.47% |
| Dec 31, 2024 | 363.50M | -49.80% |
| Dec 29, 2023 | 724.08M | -21.32% |
| Dec 30, 2022 | 920.30M | -68.57% |
| Dec 31, 2021 | 2.93B | 239.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Inhibrx Biosciences | 1.01B |
| Aktis Oncology | 1.01B |
| Compass Therapeutics | 981.48M |
| uniQure | 976.71M |
| Xeris Biopharma Holdings | 967.34M |
| GH Research | 952.77M |
| CytomX Therapeutics | 927.52M |
| Fortrea Holdings | 906.95M |